BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260714T150000
DTEND;TZID=America/Los_Angeles:20260714T160000
DTSTAMP:20260704T161356
CREATED:20260622T155750Z
LAST-MODIFIED:20260622T155750Z
UID:44319-1784041200-1784044800@solvecfs.org
SUMMARY:Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
DESCRIPTION:In 2025\, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study\, “Low Dose Rapamycin in ME/CFS\, Long-COVID\, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).   \nThe study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid\, repurposing rapamycin to reduce fatigue\, orthostatic intolerance\, post-exertional malaise\, and sleep issues for a subset of people with ME/CFS. \nIn this webinar hosted by Solve M.E. President Emily Taylor\, panelists Courtney Miller (Board President at Simmaron)\, Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron)\, and Dr. Avik Roy (Chief Scientific Officer at Simmaron) will discuss the latest learnings from the study\, and their plan to conduct an  NIH exploratory treatment trial based on the data. 
URL:https://solvecfs.org/event/repurposing-rapamycin-a-report-on-the-first-biomarker-driven-treatment-trial-for-me-cfs/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/06/July14SimmaronWebinar2.png
END:VEVENT
END:VCALENDAR